Trials / Terminated
TerminatedNCT03471351
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Rhizen Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenalisib | Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W |
| BIOLOGICAL | Pembrolizumab | Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W |
Timeline
- Start date
- 2018-07-18
- Primary completion
- 2019-02-13
- Completion
- 2019-02-13
- First posted
- 2018-03-20
- Last updated
- 2019-12-27
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03471351. Inclusion in this directory is not an endorsement.